溶栓胶囊的功效拓展(中英文)
- 格式:doc
- 大小:29.00 KB
- 文档页数:1
溶栓胶囊的功效拓展
Plasmin capsule Function expansion
为了更好地救治患者,开辟市场容量,公司不断加大投入,特别是秉承《黄帝内经》“治已病、防未病”的养生防病谋略,与中国科学院生命科学院、青海省高原医学研究院、浙江大学合作,拓展产品功能。
通过新适应症、新机理、新药效研究,溶栓胶囊已由原先的单纯治疗心脑血管疾病拓展到抗高原反应、老年痴呆症、幼儿脑瘫、脂肪肝等新领域。
临床表明,溶栓胶囊对小儿脑瘫有很好的治疗康复作用,通过减低脑内血管阻力,增加患儿的颅内供血,使大脑功能得到进一步改善。
使得患儿的综合功能提高,包括认知,生活自理,运动等方面的改善。
可作为治疗小儿脑瘫的首选药物。
目前抗高原反应、老年痴呆症、幼儿脑瘫、脂肪肝的治疗与预防为国际难题。
更为忧心的是,老年痴呆正逐渐年轻化,从65岁提前到55岁,整整提前了10年。
脂肪肝的平均发病率为25%;肥胖人群与Ⅱ型糖尿病患者中脂肪肝的发病率为50%;嗜酒和酗酒者脂肪肝的发病率为58%;在经常失眠、疲劳、不思茶饭、胃肠功能失调的亚健康人群中脂肪肝的发病率约为60%。
近年来脂肪肝人群的年龄也不断下降,平均年龄只有40岁,30岁左右的病人也越来越多。
45岁以下男性脂肪肝明显多于女性。
脑瘫儿童由于没有有效的治疗药品,很多家庭只能选择放弃,使一些脑瘫患儿错过了最佳治疗期,造成了终身残疾。
而溶栓胶囊的全世界推广,将极大的造福于全世界。
In order to better treat patients, open up the market capacity, the company continued to increase investment,In particular, adherinto the Yellow Emperor "rule has been ill for treating disease," the health disease prevention strategies, and with the Araliaceae College of Life Science,Institute of High Altitude Medicine, Qinghai Plateau Institute of Medical Research, Zhejiang University, the
expansion of product features。
Adoption of new indications, new mechanisms, new efficacy studies, plasmin capsule research has from the original capsule thrombolytic treatment of cardiovascular and cerebrovascular diseases simply extended to the anti-altitude sickness, Alzheimer's disease, children with cerebral palsy, and fatty liver of other new areas 。
Clinical show that plasmin capsule on children with cerebral palsy have a good effect of treatment and rehabilitation, by reducing vascular resistance, increased intracranial blood of children, so that further improvement of brain function. Allows children to improve the comprehensive functions, including cognition, daily living, sports and other improvementsl. Can be used as Preferred drug for treatment of children with cerebral palsy. At present,the anti-altitudesickness, Alzheimer's disease, children with cerebral palsy, treatment of fatty liver treatment and prevention is more worried about the international problem is, Alzheimer's gradually younger, from 65 to 55 years in advance, exactly 10 years earlier . The averageincidence of fatty liver was 25%, obesity and type Ⅱdiabetic patients the incidence of fatty liver was 50%.Alcohol and alcoholic fatty liver disease was 58%. In the current insomnia, fatigue, do not think Tea Food, gastrointestinal disorders health groups in the incidence of fatty liver is about 60%.Age of fatty liver in recent years has been declining, the average age of only 40 years old,30-year-old patient more and more. Male under the age of 45, significantly more than women with fatty liver. Children with cerebral palsy lack of effective treatment drugs, many families can only choose to give up, so that some children with cerebral palsy missed the best treatment period, resulting in permanent disability. The plasmin capsule around the world to promote thrombolysis, will greatly benefit the world.。